Skip to content

Evaluation of the efficacy of Yinqiao Baiyi Decoction in treating mild patients with COVID-19

Evaluation of the efficacy of Yinqiao Baiyi Decoction in treating mild patients with COVID-19

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006746
Enrollment
Unknown
Registered
2022-11-04
Start date
2022-11-10
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

The First Affiliated Hospital to Henan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Patients with mild COVID-19; ? Age 18-80 years old; ? Voluntarily accept treatment and sign informed consent.

Exclusion criteria

Exclusion criteria: ? delirious, consciousness disorder, dementia, all kinds of mental patients; ? Pregnant and lactating women; ? Patients with active pulmonary tuberculosis, pulmonary abscess and chronic respiratory failure; ? Patients with tumor; ? Patients with severe liver and kidney diseases; ? patients with severe cardiovascular and cerebrovascular diseases; ? those who are taking part in clinical trials of other drugs and are known to be allergic to the treatment drugs.

Design outcomes

Primary

MeasureTime frame
Nucleic acid turning negative time;Nucleic acid conversion rate;

Secondary

MeasureTime frame
Cumulative incidence of adverse events;rate to the normal/heavy;Time/rate of the abatement of fever;Time/rate of clinical symptom remission;

Countries

China

Contacts

Public ContactLi Suyun
lisuyun2000@126.com0371-66248624

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026